Oncology

Combining drug trametinib with a superagonist can stimulate activity while preserving the cancer-blocking effects of the treatment.

Plant produces compounds that treat cancer, arrhythmia, and other medical problems.

HDAC inhibitors in combination with immune-stimulating agents improve tumor response.

New technique could soon move to clinical trials in prostate cancer.

Individualized approach allows for creation of widespread models of patient-specific tumors.

DNA screening technology up to 10,000 times more sensitive than current tests for cancer and HIV.

Human epidermal growth factor receptor linked to success of chemotherapy.

Bright white light therapy shows treats depressive symptoms in cancer patients.

Clinical benefit of 3 to 8 months found in some patients who received drugs that targeted tumors in the P13K/AKT/mTOR pathway.

Recurrence Score test may help some women with breast cancer be spared of chemotherapy without experiencing disease progression.

Chronic CIPN is a common side effect of chemotherapy that appears a month after treatment for cancer.

Recent advances and updates in oncology and cancer drug development.

Trioxacarcins disrupt cancer cell replication by binding and chemically-modifying genetic material.

Mucus can form a shield around cancerous cells to protect from chemotherapy drugs.

Mesothelioma is resistant to available drugs, requiring the need for new treatments.

Low levels of a specific protein in colorectal cancer offers potential treatment target.

Gene activity in lung tumors offers the potential to respond to chemotherapy.

Evista is typically given to women after menopause to treat and prevent osteoporosis and reduce the risk of invasive breast cancer.

Kinase inhibitors sorafenib and sunitinib found no more effective than placebo preventing disease recurrence after kidney tumor removal surgery.

Learning what doesn't work in the treatment of cancer still offers valuable insight.

Biomarkers help predict viable candidates for successful chemotherapy treatment for stage II colon cancer.

Nanoparticles selectively target tumor vessels or cancerous cells.

Stimulator of interferon gene agonists may offer hope in the treatment of in lymphoma, multiple myeloma, and certain forms of leukemia.

Genetic and molecular specialized testing may improve targeted therapy for skin cancer.

New generation of oncology drugs could improve treatment for patients with therapy-resistant cancer.

Recent advances and updates in oncology and cancer drug development.

The targeted multi-kinase inhibitor sorafenib is the standard of care for advanced HCC, but it has limited therapeutic benefit.

Subset of T cells can confer therapeutic immune responses.